Thema: Presse: MDS to produce brain cancer drug
Presse: MDS to produce brain cancer drug
Katja[a]
22.04.2006 20:58:27
News Story
MDS to produce brain cancer drug
By Ottawa Business Journal Staff
Wed, Apr 19, 2006 10:00 AM EST
MDS Nordion has signed a three-year contract with Bradmer Pharmaceuticals for the development and clinical trial supply of Neuradiab, an antibody used to treat the most common and deadly form of brain cancer.
"We are pleased that our world-class facilities, wealth of expertise and dedication to bringing products to market quickly will contribute to Neuradiab´s development and its potential success," says MDS Nordion president Steve West.
Neuradiab is in clinical trials. It has been proven to be safe and effective in delivering tumor-killing radiation specifically to residual brain tumor cells following surgery, with minimal impact on the surrounding brain tissue.
"In six completed clinical trials involving over 160 cancer patients, Neuradiab has demonstrated a significant survival benefit over historical controls," says Dr. Mark Rogers, CEO of Bradmer Pharmaceuticals.
"This new agreement is an important step in our preparation for a planned multi-centre clinical trial for Neuradiab. We chose MDS Nordion based on their experience and standards of quality in developing and producing radiotherapeutics."
Neuradiab was developed at Duke University Medical Center in North Carolina.
MDS to produce brain cancer drug
By Ottawa Business Journal Staff
Wed, Apr 19, 2006 10:00 AM EST
MDS Nordion has signed a three-year contract with Bradmer Pharmaceuticals for the development and clinical trial supply of Neuradiab, an antibody used to treat the most common and deadly form of brain cancer.
"We are pleased that our world-class facilities, wealth of expertise and dedication to bringing products to market quickly will contribute to Neuradiab´s development and its potential success," says MDS Nordion president Steve West.
Neuradiab is in clinical trials. It has been proven to be safe and effective in delivering tumor-killing radiation specifically to residual brain tumor cells following surgery, with minimal impact on the surrounding brain tissue.
"In six completed clinical trials involving over 160 cancer patients, Neuradiab has demonstrated a significant survival benefit over historical controls," says Dr. Mark Rogers, CEO of Bradmer Pharmaceuticals.
"This new agreement is an important step in our preparation for a planned multi-centre clinical trial for Neuradiab. We chose MDS Nordion based on their experience and standards of quality in developing and producing radiotherapeutics."
Neuradiab was developed at Duke University Medical Center in North Carolina.
Katja[a]
